SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

CervoMed Presents Interim Neflamapimod Data at CTAD 2026

The 24-week interim data showed an exposure-dependent reduction in a neurodegeneration biomarker, neurofilament light, in nonfluent variant primary progressive aphasia.

CRVO

Related stories